Update on pharmacology of obesity: Benefits and risks

Lucio Cabrerizo García¹, Ana Ramos-Levi¹, Carmen Moreno Lopera², Miguel A. Rubio Herrera¹

Abstract

The prevalence of obesity in Western countries has increased at a much greater pace than the development of new efficient and safe drugs, beyond mere lifestyle changes, for the treatment of overweight. Numerous different types of drugs which had been used in the past for the treatment of obesity have currently been withdrawn due to undesirable long-term side effects. The only available drug in Europe is orlistat, which serves only as an aid for the treatment of obesity. In the USA, however, a few central adrenergic mediators, for instance, diethylpropion and phentermine, have been available for decades to treat obesity during a short-term period (less than 12 weeks). The Food and Drug Administration (FDA) has recently approved lorcaserine and the combination phentermine/topiramate for the treatment of obesity. The first one is a selective serotonin 2C receptor agonist that works by decreasing food intake with few side effects. Its outcomes on weight are modest, but may be helpful in certain selected patients. The phentermine/topiramate combination has proved to be highly effective, achieving a 10% reduction in weight in the majority of patients, although attention must be drawn to the possible development of side effects in both the short and the long-term follow-up. Further investigation regarding the mechanisms involved in weight balance will anticipate the development of new expectations for the treatment of obesity in the near future.

Nutr Hosp 2013; 28 (Supl. 5):121-127


The historical progress of drug therapy for obesity has been discouraging, since no drug has achieved a long-term favorable benefit-risk ratio. Beginning with the first thyroid hormone extracts that were used in the late 19th century, continuing with amphetamines and other sympathetic-activator drugs, and the most recent sibutramine and rimonabant, both with central and peripheral action, side effects have repeatedly outweighed benefits, forcing international regulatory agencies to subsequently proceed to their withdrawal¹ (table I). With the exception of orlistat, which is still available for the long term treatment of obesity (> 12 months), only a few adrenergic drugs are accessible exclusively in the USA for the short-term treatment of obesity, i.e., < 12 weeks (table II).

Undoubtedly, obesity entails a major healthcare problem which affects 24% of adult Spanish population³ and for which no real effective methods are available for its management. Conventional approaches based on...
lifestyle interventions reach, at the most, 5-10% weight loss at 6-12 months’ follow-up, but adherence to treatments is scarce, and weight recovery is commonly observed in the long-term. The search for a drug with the best benefit-risk ratio should include the achievement of at least a 10-20% weight loss, which would imply an intermediate effect between the modest outcomes of lifestyle interventions (5-10%) and those of the simplest bariatric surgery technique (20-30%). For this reason, the FDA considers that a suitable drug for the treatment of obesity should comply with the following characteristics: a) a significantly different weight loss (> 5%) in comparison to placebo after one year of treatment and b) that the number of individuals reaching > 5% weight loss is at least 35% in comparison to placebo, with differences being statistically significant. In any case, drug treatment for obesity would be indicated in those with a body mass index (BMI) ≥ 30 kg/m² or ≥ 27 kg/m² with obesity-associated major comorbidities.

### Commercially available drugs for the treatment of obesity

In Europe, the only available drug for the treatment of obesity is orlistat. The other ones which have been already approved by the FDA in the USA are still under evaluation by the European Medicines Agency (EMA).

**Orlistat**

Orlistat is a gastric and pancreatic lipase inhibitor, which was first introduced in the market in 1998. Its mechanism of action is related to inhibition of fat absorption to approximately 30% of intake. This action entails the development of its well-known side effects, such as flatulence, increased bowel habit, voluminous stools and steatorrhea, which may occur in up to 15-20% of patients; but these have not frequently been a reason for discontinuation of treatment. Orlistat 120 mg TID achieves a 3% higher weight loss than placebo and contributes to a decrease of obesity-associated metabolic comorbidities. Further sub-analysis demonstrated that 26% of those receiving orlistat lost > 10% of total body weight, whilst 30% of this group lost > 5%, in comparison to 14% and 19% in the placebo group, respectively. The XENDOS (Xenical in the prevention of diabetes in obese subjects) study, a four-year double-blind placebo-controlled trial of 3305 non-diabetic obese patients, showed that orlistat reduced the risk of developing type 2 diabetes by 37.3% compared to placebo (lifestyle modification). Orlistat is the only currently available drug whose technical data sheet includes obesity as an indication of use. However, 32 alerts of severe hepatic failure, together with some cases of pancreatitis and renal oxalate calculi, have decreased its popularity.
Drugs that have been used to treat obesity, but that are not approved by regulatory agencies for this purpose

Bupropion

Bupropion, which inhibits the reuptake of norepinephrine and dopamine, is approved for the treatment of depression and smoking cessation. These neurotransmitters are involved as well in the regulation of food intake. In a study in which 327 obese subjects were randomized to placebo, bupropion 300 mg/d, or bupropion 400 mg/d, at 24 weeks, body weight was reduced by 5.0%, 7.2%, and 10.1%, respectively. The trial was extended to week 48, and weight loss in the bupropion 300-mg and 400-mg groups was 6.2% and 7.2% of the initial body weight, respectively, but the final dropout rate was 41%. The pharmaceutical company did not consider its commercialization for the treatment of obesity due to its central side effects, for instance, mouth dryness, insomnia, anxiety and palpitations, and due to the high discontinuation rate.

Combination of Bupropion and Naltrexone

Bupropion stimulates hypothalamic pro-opiomelanocortin (POMC) neurons that release alpha-melanocyte stimulating hormone (α-MSH) which, in turn, binds to melanocortin-4 receptors, and thus, favors an anorexigenic action. When α-MSH is released, POMC neurons simultaneously release β-endorphin, an endogenous agonist of the mu-opioid receptor. Binding of β-endorphin to μ-opioid receptors on POMC neurons mediates a negative feedback loop on POMC neurons leading to a decrease in the release of α-MSH. Blocking this inhibitory feedback loop with naltrexone is thought to facilitate a more potent and longer-lasting activation of POMC neurons, thereby amplifying its effects on energy balance. As a result, co-administration of bupropion and naltrexone produces a substantially greater effect on the POMC neurons, suggesting that the drugs act synergistically.

Bupropion was combined with naltrexone in its sustained release form (Contrave™). Several phase III trials, grouped under the Contrave Obesity Research (COR), have been conducted in both diabetic and non-diabetic patients: COR-I, COR-II, COR-BMOD and COR-Diabetes. The naltrexone/bupropion patients lost significantly more weight (5.0% versus 1.5%, p<0.001) at 56 weeks, with 45% of patients achieving ≥5% body weight loss, compared to 19% with placebo. This combination resulted in significant improvements in depressive symptoms in addition to weight loss, as well as in a satisfactory recovery of eating-control in overweight and obese women with major depression. This drug combination has generally been well tolerated in most patients; nausea was the most frequently reported adverse event, which was associated to higher naltrexone doses.

The FDA advisory panel voted 13 to 7 in favor of approval of this combination in December 2010; however, the FDA declined to approve the drug in February 2011, claiming that cardiovascular safety should be proved in a specific large-scale long-term trial, before it could be reconsidered for evaluation. This was an unexpected decision by the FDA, given that bupropion, which is the drug potentially associated with an increased cardiovascular risk, is already available and used by millions of Americans for the treatment of mild depression or smoking cessation.

Bupropion plus zonisamide

The combination of bupropion with the antiepileptic agent zonisamide has been evaluated in phase II trials. Zonisamide’s mechanism of action has not been fully characterized; however, it has demonstrated a biphasic dopamine and serotoninergic activity. A 24-week RCT of bupropion 300 mg combined with zonisamide 400 mg achieved a greater weight loss (9.2%) than either drug alone (bupropion 6.6%, zonisamide 3.6%) or placebo (0.4%). Weight loss with zonisamide and bupropion appeared to be greater than that observed with the bupropion/naltrexone combination over the same period of treatment.

Topiramate

Topiramate is an anticonvulsant drug that was approved for use in certain types of epilepsy and for the treatment of migraine headache. Its mechanism of action is not fully understood, although several hypotheses are considered, such as blockage of voltage-activated sodium channels, inhibition of high-voltage-activated calcium channels, glutamate receptor antagonism (an orexigenic agent), inhibition of carbonic anhydrase, enhancing of gamma-aminobutric acid (GABA)-evoked currents and inhibition of kainite-evoked currents. It proved to reduce food intake, but was not further developed clinically because of side effects occurring at doses selected for trials. In a 6-month, placebo-controlled, dose-ranging study, 385 obese subjects were randomized to four topiramate doses: 64, 96, 192, or 384 mg/d, or placebo. The key to improve drug tolerance was that these doses were gradually increased over 12 weeks and were tapered down in a similar way at the end of the trial. Weight loss from baseline to 24 weeks was −5.0%, −4.8%, −6.3%, −6.3%, and −2.6% in the five groups, respectively. The most frequently reported adverse events were paresthesias (an effect due to inhibition of carbonic anhydrase), somnolence, and concentration, memory, and attention difficulties. A metaanalysis of ten randomized clinical trials (3320 individuals) were recently analyzed. Patients treated with topiramate lost an average of 5.34 kg (95% confidence interval [95% CI] −6.12 to −4.56) of additional weight as compared with placebo. In the evaluation of
trials using topiramate 96–200 mg day, the weight loss was higher in trials with >28 weeks of duration (–6.58 kg [95% CI –7.48 to –5.68]) than in trials with <28 weeks (–4.11 kg [95% CI –4.92 to –3.30]). The authors concluded that topiramate might be a useful adjunctive therapeutic tool in the treatment of obesity as long as proper warnings about side effects are considered.

**Drugs under clinical investigation**

**Cetilistat**

Like orlistat, cetilistat is a gastrointestinal and pancreatic lipase inhibitor that reduces fat absorption. In a 12-week phase-II double-blinded RCT (n = 447), cetilistat, in combination with a hypocaloric diet, produced significantly greater weight loss than placebo, with a dose-related response for 60, 120 and 240 mg TID. In a multicenter, randomized, double-blind study (n = 869) to determine the efficacy and safety of cetilistat (40, 80, or 120 mg TID) and orlistat (120 mg TID) in comparison to placebo, in obese patients with type 2 diabetes on metformin, for 12 weeks, similar reductions in body weight were observed in patients receiving cetilistat 80 or 120 mg TID or 120 mg TID orlistat; these reductions were significant vs. placebo (3.85 kg, 4.32 kg, and 3.78 kg, respectively; p < 0.001). The results are comparable to those of orlistat, with approximately 30% of the treated patients experiencing >5% weight loss compared to 19% in the placebo group. The adverse side effects of cetilistat were similar to those reported with orlistat, although such events were less frequent, suggesting a better tolerability and therefore precluding good compliance.

**Tesofensine**

Tesofensine is another novel pharmacological agent which inhibits the uptake of presynaptic noradrenaline, dopamine, and serotonin. Patients receiving this drug for the treatment of Alzheimer’s and Parkinson’s diseases reported weight loss. Further evidence was demonstrated in a 24-week phase Ib randomized dose-dependent tesofensine trial in 203 obese individuals, with 79% of completers. Weight loss was dose-dependent with 4.5% weight loss (0.25 mg), 9.2% (0.5 mg), and 10.6% (1.0 mg) and was greater than placebo (p < .001). The drug was well tolerated, with mild symptoms appearing due to its central effects: mouth dryness, constipation, insomnia, anxiety and a significant increase in heart rate (7.4 beats/min), with no associated changes in blood pressure.

**Glucagon-Like Peptide-1 (GLP1) Analogues: Liraglutide, Exenatide**

Liraglutide and exenatide are glucagon-like peptide-1 receptor analogues (GLP-1R) which were developed and approved for the treatment of type 2 diabetes. In a systematic review and metaanalysis of 25 trials, GLP-1R agonist groups achieved a greater weight loss than control groups (weighted mean difference −2.9 kg, 95% confidence interval −3.6 to −2.2; 6411 participants). GLP-1R agonists had additional beneficial effects on systolic and diastolic blood pressure, plasma concentrations of cholesterol, and glycemic control. GLP-1R agonists were associated with nausea, diarrhea and vomiting, but not with hypoglycemia. In a head-to-head comparison, liraglutide 1.2 mg and exenatide produced similar amounts of weight loss (3.24 kg with liraglutide vs 2.87 kg with exenatide); although with both treatments 17% of patients achieved a > 5% weight loss, with liraglutide 1.8 mg/d, this rate increased to 24% of patients.

A recent 20-week multicenter European dose-ranging RCT of liraglutide (1.2, 1.8 mg, 2.4 mg, 3.0 mg) in comparison with orlistat (120 mg treatment) in 564 non-diabetic obese patients, demonstrated a mean weight loss of 4.8 kg, 5.5 kg, 6.3 kg, and 7.2 kg, respectively, compared with 2.8 kg in the placebo-treated group and 4.1 kg in the orlistat-treated group. Higher doses of liraglutide (3.0 mg) demonstrated significantly greater mean weight loss than placebo or orlistat. A total of 76% achieved at least a 5% weight loss compared with 30% in the placebo group, and 44% in orlistat group. Liraglutide reduced blood pressure at all doses, and reduced the prevalence of prediabetes (84–96% reduction) with 1.8–3.0 mg per day. Nausea and vomiting occurred more frequently in individuals on liraglutide than in those with placebo; yet adverse events were mainly transient and rarely led to discontinuation of treatment.

**Drugs approved by FDA advisory panels**

The US FDA has recently approved 2 new drugs for the treatment of obesity: Lorcaserin and a combination of Phentermine plus Topiramate.

**Lorcaserin (Belviq™)**

Lorcaserin is a selective serotonin subtype 2C receptor agonist on hypothalamic pro-opiomelanocortin neurons, which leads to reduced caloric intake and increased satiety. It is similar in its mechanism of action to fenfluramine and dexfenfluramine, except for that it is specific for the 2C subtype serotonin receptor, which is not found in the heart or heart valves (these two are linked to serotonin subtypes 5A or 5B receptors). The result is thought to be a compound effect of a desirable increased satiety and an inhibition of hunger, with no heart valve damage.

The tolerability and efficacy of lorcaserin for the treatment of obesity have been evaluated in 3 large RCT, placebo-controlled, double-blind studies, which
provided the basis for FDA approval in June 27, 2012. In the BLOSSOM (Behavioral Modification and Lorcaserin Second Study for Obesity Management) trial, 4008 obese or overweight patients with obesity-related comorbid conditions were randomized to receive either lorcaserin 10 mg QD (n = 801), lorcaserin 10 mg BID (n = 1602), or placebo (n = 1601) for 52 weeks. A total of 2224 (55.5%) completed the 1-year trial. Absolute weight loss was 5.8 kg, 4.7 kg, and 2.9 kg for lorcaserin BID, lorcaserin QD, and placebo, respectively. More subjects receiving lorcaserin BID (47.2%) and lorcaserin QD (40.2%) lost at least 5% body weight at 1 year than placebo (25%), with differences being statistically significant. On the other hand, although systolic and diastolic blood pressure and heart rate decreased in all groups, differences were not statistically significant in this case.

The BLOOM (Behavioral Modification and Lorcaserin for Overweight and Obesity Management) study evaluated 3182 patients for up to 2 years with similar results (~5.8 kg for lorcaserin, compared with ~2.2 kg for placebo). On the other hand, the BLOOM-DM (Behavioral Modification and Lorcaserin for Obesity and Overweight Management in Diabetes Mellitus) study evaluated the safety and efficacy of lorcaserin in 604 patients with type 2 diabetes, with glycosylated hemoglobin (HbA1c) of 7-10%, and treated with either metformin, sulfonylurea, or both. Absolute weight loss was approximately 5 kg for lorcaserin and 1.6 kg for placebo. The study found that 45% on lorcaserin QD and 16% on placebo achieved at least a 5% weight loss. Approximately half of the patients in the lorcaserin treatment arm achieved an HbA1c level <7%, almost twice the rate in the placebo group. It is not clear at this time, however, whether lorcaserin has effects on glycemic control that are independent of weight loss.

On the basis of the results of these studies, lorcaserin was approved at a dose of 10 mg BID in patients with BMI $\geq$ 30 kg/m$^2$, or BMI $\geq$ 27 kg/m$^2$ and at least one weight-related comorbidity, such as hypertension, type 2 diabetes, or dyslipidemia, in addition to a reduced-calorie diet and an increased physical activity. This therapy should be assessed at week 12 and if there is a < 5% decrease in weight, use of the drug should be discontinued because it is unlikely that the patient will achieve and sustain an adequate weight loss with continued treatment.

The most common adverse events with lorcaserin include headache, dizziness, nausea, constipation, fatigue, and mouth dryness. Although lorcaserin meets FDA weight loss criteria, the efficacy is modest, but the risk profile is also low. Lorcaserin treatment demonstrates an approximate average of 3 kg weight loss in a patient weighing 100 kg, or a reduction of 1.2 kg/m$^2$ in BMI, where the basal mean BMI is 36.1 kg/m$^2$. It is prudent to identify potential “responder patients”, who will benefit from treatment, and differentiate them from other patients in which efficacy will not be likely, especially considering the fact that the estimated cost is approximately US$ 1500 per year or US$ 265 for each kilogram lost.

Combination of phentermine and topiramate (Qsymia™, Qsiva™)

The drug combination of phentermine and topiramate (PHEN/TPM) was also recently approved by the FDA. Phentermine is a central noradrenergic drug that was commercialized in 1956 as monotherapy (15-30 mg/d) to induce a decreased appetite and favor weight loss in obese patients, but only for short-term use (< 12 weeks). Topiramate monotherapy (200-400 mg/d) was approved in 1996 for the treatment of partial seizures and in 2004 for migraine prophylaxis. The combination of PHEN/TPM allows a lower dose of both phentermine and controlled-release topiramate, and thus provides a more acceptable side-effects profile. The tolerance and safety of this drug combination are being evaluated in several phase III trials, comparing different dosages PHEN/TPM: low-dose (3.75/23 mg), mid-dose (7.5/46 mg), and high-dose (15/92 mg).

The EQUIP trial (Controlled-Release Phentermine/Topiramate in Severely Obese Adults: A Randomized Controlled Trial) included people aged 18 to 70 years with a BMI of ≥ 35 kg/m$^2$ who were randomized to PHEN/TPM 15 mg/92 mg (n = 512), PHEN/TPM 3.75 mg/23 mg (n = 241), or placebo (n = 514) for 52 weeks. The percentage of weight loss with high-dose was 10.9% (~12.6 kg), compared with 5.1% (~6 kg) in the low-dose and 1.6% (~1.8 kg) for placebo (p < 0.001 for both doses compared with placebo).

The CONQUER (Effects of Low-Dose, Controlled-Release, Phentermine Plus Topiramate Combination on Weight and Associated Comorbidities in Overweight and Obese Adults) trial compared full-dose and mid-dose PHEN/TPM with placebo for 56 weeks, including obese and overweight adults (BMI, 27-45 kg/m$^2$) who had 2 or more weight-related comorbidities. This trial was followed by the SEQUEL study, an extension for 1 additional year. At the end of the CONQUER study, the percentage weight loss was 9.8% (10.2 kg for high-dose, 7.8% (8.1 kg) with mid-dose, and 1.2% (1.8 kg) for placebo (p < 0.001 for both doses vs placebo). Approximately 70%, 62% and 21%, reached at least 5% weight loss, respectively. Weight loss was maintained during the second year of treatment in completers (SEQUEL study), resulting in 10.5% (10.9 kg) in PHEN/TPM 15/92 mg, 9.3% (9.6 kg) in PHEN/TPM 7.5/46 mg, and 1.8% (2.1 kg) in the placebo group (p < 0.001 for both dosages vs placebo). Nearly 80% of participants receiving the top-dose attained 5% weight loss compared to 75% receiving mid-dose and 30% receiving placebo (p < 0.001 for both doses compared with placebo). The combination of PHEN/TPM achieves a high rate of adherence to treatment, similar to that obtained with orlistat, but with a clearly better efficacy (table III).
Summary of weight loss effects and dropout rates of drugs available for obesity treatment. Results at one-year follow-up (intention to treat analysis)

<table>
<thead>
<tr>
<th>Drug</th>
<th>Weight loss with drug</th>
<th>Weight loss with placebo</th>
<th>≥ 5% weight loss</th>
<th>Dropouts</th>
</tr>
</thead>
<tbody>
<tr>
<td>Orlistat</td>
<td>-6.5%</td>
<td>-3.6%</td>
<td>45%</td>
<td>30%</td>
</tr>
<tr>
<td>Lorcaserin</td>
<td>-5.8%</td>
<td>-2.5%</td>
<td>47%</td>
<td>45%</td>
</tr>
<tr>
<td>BLOOM and BLOSSOM</td>
<td>-5.8%</td>
<td>-2.5%</td>
<td>47%</td>
<td>45%</td>
</tr>
<tr>
<td>BLOOM-DM</td>
<td>-4.5%</td>
<td>-1.5%</td>
<td>38%</td>
<td>50%</td>
</tr>
</tbody>
</table>

PHE/TPM: Combination of phentermine and topiramate.

Following the outcomes of the results of these studies, PHEN/TPM was approved for the treatment of obesity in patients with a BMI ≥ 30 kg/m² or a BMI ≥ 27 kg/m² with at least one weight-related comorbidity, such as hypertension, type 2 diabetes mellitus, or dyslipidemia, in addition to a reduced caloric diet and increased physical activity. Drug combination PHEN/TPX therapy is started at 3.75 mg/23 mg, taken QD in the morning and, after 14 days can be increased to 7.5 mg/46 mg. If at 12 weeks follow-up at least 3% weight loss has not been obtained, the drug may be discontinued or the dose may be increased to 11.25 mg/69 mg for another 14-day trial, followed by a final dosage increase to 15 mg/92 mg. Weight loss should be evaluated after a period of 12 weeks, and if 5% weight loss is not achieved, therapy should be withdrawn. Annual estimated cost is approximately US$ 2200 (US$ 180 per each kilogram lost).

The most common adverse drug reactions include paresthesias, dizziness, dysgeusia, insomnia, constipation, and mouth dryness. Potential safety concerns include depression, anxiety, cognitive-related complaints (memory and attention), cardiovascular risk with a small increase of heart rate, reduced bicarbonate levels, which could exacerbate metabolic acidosis, and teratogenicity.

The combination of PHEN/TPM received a vote of 20 to 2 in favor at the February 2012 FDA Advisory Panel and was FDA approved on July 2012. However, on October 18th 2012, the Committee for Medicinal Products for Human Use (CHMP), from the European Medicines Agency, adopted a negative opinion and rejected marketing authorization for the medicinal product Qsiva, intended for the treatment of obesity. The CHMP remarked that main studies anticipated concerns regarding certain adverse effects related to cardiovascular risk, as well as in the psychiatric and cognitive fields; the Committee perceived that there was a high probability that, if approved, the drug would not be used strictly and exclusively for the intended patients. The applicant did propose specific measures to reduce this risk, but they were considered to be of difficult implementation in clinical practice. Therefore, the CHMP concluded that the benefits of Qsiva did not outweigh its risks and recommended that it were refused for marketing authorization.

Conclusions

Overweight and obesity are constant queries demanded in every day clinical practice, and attention to these issues should not be disregarded, since their associated comorbidities entail a significant increased morbidity and mortality. Lifestyle interventions and bariatric surgery for selected patients are the only two approaches currently available. Obesity-targeted drug therapies used in the past have deemed unreliable and the reality is that we are actually back at the starting point: the possibility of obtaining an ideal long-term effective and safe drug is still out of reach. The improvement of knowledge regarding physiopathology and mechanisms involved in food intake regulation and weight balance will surely help the development of specific therapies which will be available in the near future.

References

10. Wadden TA, Foreyt JP, Foster GD, Hill JO, Klein S, O’Neil PM et al. Weight loss with naltrexone SR/bupropion SR combi-
21. Niswender K, Pi-Sunyer X, Buse J, Jensen KH, Toft AD, Russell-Jones D et al. Weight change with liraglutide and con-